NephJC Shorts
Nephrology produces far more new studies each week than NephJC can realistically cover in its twice‑monthly full reviews. That’s why we’re introducing NephJC Short- quick, sharp summaries of notable papers that caught the editorial team’s attention. Suggestions welcome, and feedback too.
🩳Read more on the blog post describing this initiative.
Upcoming NephJC Shorts
DIalysis Symptom COntrol-Pruritus Outcome Trial (DISCO-POT): A Multicenter Randomized Blinded Placebo-Controlled Crossover Trial (Collister D et al, Kidney Med, 2026)
Once a patient with septic shock has received the first liter, what comes next? ARISE FLUIDS reshapes the ED shock strategy before 30 mL/kg: more fluid or earlier vasopressors?
First trial in pregnancy and CKD after 30 years - aiming to test feasibility of nitrate administration in pregnant women with CKD
Non-dialyzable beta-blockers showed lower MACE, but the study was observational and shaped by regional prescribing habits that may hide confounding factors.
Iptacopan decreases proteinuria, now we get the 24-month eGFR data in patients with IgA Nephropathy.
Does Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?
Can polymyxin B hemadsorption truly shift the fate of septic shock, or is the outcome already written?
Water, water everywhere. Can a wink, a nudge and a push increase water intake to decrease kidney stone formation?
The NephJC shorts on cost-efficiency of low-protein diets and ketoanalogues as a distraction from CKD-relevant therapies in the 21st century… wait, only if the comparator wouldn’t be dialysis.
The NephJC shorts version of the Hypertension medication step-down in a nursing home population from NEJM
